Containing the highest molecular weight hyaluronic acid in the UK, and now with very competitive pricing, more equine practices are using Pfizer Animal Health’s Hylartil as their preferred treatment option for the management of equine degenerative joint disease.
Containing the highest molecular weight hyaluronic acid (HA) in the UK and now with very competitive pricing, more equine practices are using Pfizer Animal Health’s Hylartil as their preferred treatment option for the management of equine degenerative joint disease (DJD).
DJD is one of the most common causes of lameness in horses. Progressive damage to the joint causes inflammation and pain which has an impact on the horse’s ability to perform at its best. The two main goals for the medical treatment of DJD are to reduce pain and to minimise progression of joint deterioration.
Injecting therapeutic HA into the joint aims to replace the HA that is lost in DJD and stimulate the production of natural HA – essential to lubricate the joint, reduce inflammation and pain and increase mobility.
High molecular hyaluronic acids are considered to have superior efficacy: the functional mechanisms of HA are directly dependent on the molecular weight and concentration of HA. Therefore, the high molecular weight preparations are recommended due to their increased efficacy and duration of action.
Hylartil contains the highest molecular weight HA in the UK. It is presented in a pre-loaded 2ml sterile syringe for convenience. It is the only HA also indicated for tendinitis and can be administered intra-articularly or directly into the tendon.
- For further information contact your Pfizer Account Manager.